{"product_id":"ryzneuta-efbemalenograstim-alfa","title":"Ryzneuta (Efbemalenograstim alfa)","description":"\u003cp\u003eRyzneuta® (Efbemalenograstim alfa-vuxw), sold under the brand name 亿立舒® in china, is a leukocyte growth factor used for reducing the incidence of infection, as manifested by febrile neutropenia (FN), in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer medicines associated with a clinically significant incidence of febrile neutropenia (FN). \u003c\/p\u003e\u003cp\u003eIt was approved for medical use in China in May 2023, and the United States in November 2023.\u003c\/p\u003e\u003cp\u003eNovember 16, 2023 – The FDA approved Evive Biotechnology’s Ryzneuta (efbemalenograstim alfa-vuxw), to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.\u003c\/p\u003e","brand":"Evive Biotech, China","offers":[{"title":"Default Title","offer_id":44797952131115,"sku":"RL23202402","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-01-2233.jpg?v=1787022167","url":"https:\/\/xomeds.com\/products\/ryzneuta-efbemalenograstim-alfa","provider":"XOMEDS","version":"1.0","type":"link"}